预约演示
更新于：2025-12-04
Ethinylestradiol/Levonorgestrel
左炔诺孕酮/炔雌醇
更新于：2025-12-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1982-05-10), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C41H52O4 |
InChIKeyORKBYCQJWQBPFG-WOMZHKBXSA-N |
CAS号39366-37-5 |
关联
127
项与 左炔诺孕酮/炔雌醇 相关的临床试验NCT07190430
A Phase 1, Open-label, Fixed Sequence Study to Evaluate The Effect of Steady-State Dosing of PF-08049820 on the Single Dose Pharmacokinetics of Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
NCT07074327
Phase 1, Open-label Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Subjects
NCT06942936
An Open-label, Fixed-sequence and Two-part Study to Assess the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on the Pharmacokinetics of Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
100 项与 左炔诺孕酮/炔雌醇 相关的临床结果
登录后查看更多信息
100 项与 左炔诺孕酮/炔雌醇 相关的转化医学
登录后查看更多信息
100 项与 左炔诺孕酮/炔雌醇 相关的专利（医药）
登录后查看更多信息
703
项与 左炔诺孕酮/炔雌醇 相关的文献（医药）2025-11-01ATHEROSCLEROSIS
Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization
Article
作者: Caruana, P ; Tondo, M ; Pepe, A ; Céspedes, M V ; Martínez, A ; Borràs, C ; Escola-Gil, J C ; Prades, R ; Cenarro, A ; Llorente-Cortés, V ; Garcia, E ; Civeira, F ; Benitez-Amaro, A ; La Chica Lhoëst, M T ; Bochicchio, B
BACKGROUND AND AIMS:
Low-density lipoprotein (LDL) aggregation is nowadays considered a therapeutic target in atherosclerosis. DP3, the retro-enantio version of the sequence Gly1127-Cys1140 of LRP1, efficiently inhibits LDL aggregation and foam cell in vitro formation. Here, we investigate whether DP3 modulates atherosclerosis in a humanized ApoB100, LDL receptor (LDLR) knockout mice (Ldlr-/-hApoB100 Tg) and determine the potential LDL-related underlying mechanisms.
METHODS:
Tg mice were fed an HFD for 21 days to induce atherosclerosis and then randomized into three groups that received a daily subcutaneous administration (10 mg/kg) of i) vehicle, ii) DP3 peptide, or iii) a non-active peptide (IP321). The in vivo biodistribution of a fluorescent-labeled peptide version (TAMRA-DP3), and its colocalization with ApoB100 in the arterial intima, was analyzed by imaging system (IVIS) and confocal microscopy. Heart aortic roots were used for atherosclerosis detection and quantification. LDL functionality was analyzed by biochemical, biophysical, molecular, and cellular studies.
RESULTS:
Intimal neutral lipid accumulation in the aortic root was reduced in the DP3-treated group as compared to control groups. ApoB100 in LDLs from the DP3 group exhibited an increased percentage of α-helix secondary structures and decreased immunoreactivity to anti-ApoB100 antibodies. LDL from DP3-treated mice were protected against passive and sphingomyelinase (SMase)-induced aggregation, although they still experienced SMase-induced sphingomyelin phospholysis. In patients with familial hypercholesterolemia (FH), DP3 efficiently inhibited both SMase-induced phospholysis and aggregation.
CONCLUSIONS:
DP3 peptide administration inhibits atherosclerosis by preserving the α-helix secondary structures of ApoB100 in a humanized ApoB100 murine model that mimicks the hallmark of human hypercholesterolemia.
2025-08-01CURRENT OPINION IN PEDIATRICS
Contraception updates for adolescents
Review
作者: Carleen, Anna ; Ebersole, Ashley
Purpose of review:
To discuss updated guidelines for the provision of contraception to adolescents, review several contraceptive methods that have entered the market in recent years, and summarize insights from the literature that can assist clinicians in providing accurate, destigmatized contraceptive counseling to patients of all sizes.
Recent findings:
The 2024 United States Selected Practice Recommendations (US SPR) and United States Medical Eligibility for Contraceptive Use (US MEC) guidelines include changes to recommendations for contraception use in persons with various health conditions, and new advice for management of implant-associated breakthrough bleeding, pain control for intrauterine device (IUD) insertions, and counseling for patients who take testosterone. Subcutaneous Depo-Provera usage increased during the COVID-19 pandemic, and multiple studies demonstrate favorable patient experiences with it. Annovera, Miudella, Opill, Phexxi, Slynd, and Twirla are newer contraceptives which have distinct features that may make them attractive options for some patients. Contraception-related weight changes continue to be an active area of research. With the Food and Drug Administration (FDA) recommending broader BMI inclusion criteria, providers can expect more information about safety and efficacy of new contraceptives in individuals across the weight spectrum.
Summary:
Updated evidence-based guidelines and several new contraceptive options should empower providers to provide patient-centered contraception counseling to patients with a variety of health conditions and contraceptive preferences.
2025-05-01Acta Biomaterialia
A highly transparent dopamine-copolymerized hydrogel with enhanced ROS-scavenging and tissue-adhesive properties for chronic diabetic wounds
Article
作者: Zhang, Haiqi ; Wang, Jinze ; Ma, Lie ; Hu, Hongtao
Chronic diabetic wounds with complex symptoms represent a major challenge in clinical practice, causing a serious threat to human health and life. Excessive oxidative stress and persistent inflammatory responses are the important reasons for the long-term difficult healing of diabetic wounds. Designing wound dressing materials with intrinsic antioxidant performance, high transparency, adhesiveness, and favorable mechanical properties is of great significance for promoting wound healing, especially in movable parts. Here, a dopamine-copolymerized highly transparent antioxidant hydrogel was developed for the treatment of chronic diabetic wounds. The hydrogel was easily prepared via free radical polymerization using acrylated dopamine monomer (ADA), acrylamide (AM), and phenylboronic acid modified dextran (DP). The dynamic phenylborate ester bonds formed between the catechol of polydopamine and phenylboronic acid effectively mitigated the darkening of the hydrogel color caused by the auto-oxidation of catechol, resulting in the PAM/PDA/DP hydrogel (DP3) with durable transparency. In addition, this hydrogel had good adhesiveness and mechanical properties, as well as desirable reactive oxygen species (ROS)-scavenging performance. Furthermore, in vivo results demonstrated that DP3 hydrogel can stimulate the polarization of macrophages toward anti-inflammatory M2 phenotype, increase the secretion of anti-inflammatory factors, so as to smooth the transition of wound healing from the inflammatory phase to the proliferative phase, and accelerate the repair of diabetic wounds by promoting angiogenesis and collagen deposition. Therefore, the DP3 hydrogel holds great potential for remolding the tissue regeneration microenvironment and serving as a promising dressing for chronic diabetic wounds. STATEMENT OF SIGNIFICANCE: Polydopamine (PDA)-based hydrogels have been widely explored. However, existing PDA-based hydrogels suffer from low content of catechol groups and inferior transparency, and are prone to oxidation darkening during storage. In this study, a dopamine-copolymerized hydrogel with high catechol content was developed. The catechol groups are partially protected by phenylboronic acid-modified dextran, resulting in durable transparency and good adhesiveness of the hydrogel. The hydrogel exhibits desirable antioxidant performance and can effectively promote chronic diabetic wound healing by relieving oxidative stress and regulating immune function. This highly transparent hydrogel with intrinsic antioxidation and self-adhesiveness properties represents a potential and effective strategy for chronic wound management.
75
项与 左炔诺孕酮/炔雌醇 相关的新闻（医药）
2024-10-21
100 项与 左炔诺孕酮/炔雌醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 痛经 | 日本 | 2018-07-02 | |
| 避孕 | 美国 | 1982-05-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无先兆偏头痛 | 临床2期 | 美国 | 2009-01-01 | |
| 出血 | 临床2期 | 美国 | 2006-10-01 | |
| 子宫不规则出血 | 临床2期 | 美国 | 2006-10-01 | |
| 丙型肝炎 | 临床1期 | 比利时 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 2,032 | 鹹膚膚範蓋襯簾顧鏇製(壓範顧齋簾繭廠壓遞鬱) = 繭憲繭鏇選鹹繭鬱壓襯 糧選製鏇簾鏇鑰齋鏇膚 (膚糧夢遞醖窪膚鹽鹹醖 ) 更多 | 积极 | 2021-03-01 | |||
临床2期 | 51 | IBD98-M (High Dose Group) | 糧製鏇築鏇鑰積壓襯廠 = 選淵襯繭壓積觸積夢夢 淵選顧憲糧憲構糧構觸 (製鬱襯製鬱壓蓋選艱鬱, 鑰選鹽糧鹽衊構製繭積 ~ 鹽廠襯簾糧餘鑰膚獵夢) 更多 | - | 2020-08-14 | ||
IBD98-M (Low Dose Group) | 糧製鏇築鏇鑰積壓襯廠 = 鏇艱願製憲鑰艱繭衊鹽 淵選顧憲糧憲構糧構觸 (製鬱襯製鬱壓蓋選艱鬱, 壓壓襯齋壓範鹹蓋簾齋 ~ 遞淵廠簾顧廠製鑰獵醖) 更多 | ||||||
临床4期 | 17 | (Ritonavir) | 範餘鬱繭鑰鹹製願醖願(壓齋鑰鬱壓鬱壓繭鬱艱) = 簾醖淵鏇醖衊餘憲顧鑰 鏇廠憲夢膚鬱鏇觸願夢 (積艱鏇構遞艱鏇遞鑰廠, 61) 更多 | - | 2019-05-31 | ||
(Control) | 範餘鬱繭鑰鹹製願醖願(壓齋鑰鬱壓鬱壓繭鬱艱) = 膚顧餘獵觸網鬱憲積襯 鏇廠憲夢膚鬱鏇觸願夢 (積艱鏇構遞艱鏇遞鑰廠, 83) 更多 | ||||||
临床1期 | - | 24 | EE+LNG (AG200-15) | 鏇餘繭觸鹽蓋餘糧鬱膚(膚餘構範築襯遞壓窪憲) = 鬱鏇遞襯窪齋鹽膚廠壓 願鬱鏇廠憲艱壓艱憲淵 (繭壓鏇廠製鑰鏇鹽網範, 998) 更多 | - | 2018-12-31 | |
EE+LNG (AG200-15 on Lower Abdomen) | 鏇夢繭餘簾鏇簾築繭糧(廠膚襯餘壓鹽願構鏇夢) = 鑰選艱製範製壓顧繭遞 範鑰襯網襯鏇願願觸壓 (淵窪鹽鬱淵觸蓋鏇選齋, 構艱製獵鹽遞襯構齋憲 ~ 憲艱糧艱蓋鑰鬱選選壓) 更多 | ||||||
临床2期 | - | 123 | (AG200LE) | 網網獵願艱壓餘簾築鏇 = 選願鹹築憲簾齋齋築製 夢廠簾積築壓艱製鏇夢 (齋鹽簾糧選廠遞壓蓋憲, 選觸範糧衊鬱壓艱鬱壓 ~ 齋鏇築構鹹艱觸壓選積) 更多 | - | 2018-07-05 | |
網網獵願艱壓餘簾築鏇 = 憲醖遞觸繭醖願遞糧鏇 夢廠簾積築壓艱製鏇夢 (齋鹽簾糧選廠遞壓蓋憲, 窪積觸衊鏇醖窪鏇繭範 ~ 糧顧齋醖壓蓋繭夢鹹壓) 更多 | |||||||
临床3期 | 1,504 | (AG200-15 for Cycle 7-13) | 鏇繭衊遞襯觸鑰繭廠選 = 積醖衊窪願鏇餘憲醖積 遞蓋醖觸積構鹹鹹鑰構 (鹽構選簾鏇淵淵膚構獵, 淵艱獵觸製鏇醖窪鹹範 ~ 鬱醖廠網襯窪醖觸糧齋) | - | 2018-07-03 | ||
Lessina (Lessina) | 鏇繭衊遞襯觸鑰繭廠選 = 衊壓齋鏇憲製繭網築齋 遞蓋醖觸積構鹹鹹鑰構 (鹽構選簾鏇淵淵膚構獵, 膚餘襯選鑰鑰膚遞鹹鬱 ~ 艱醖憲齋願憲積鏇衊壓) 更多 | ||||||
临床1期 | - | 36 | (Ortho-Cyclen®) | 獵餘繭鬱餘艱餘壓鑰獵(顧廠築觸鬱鏇糧網鑰鏇) = 襯鑰積獵顧糧觸餘構鬱 遞淵積鑰選繭蓋膚鹽廠 (艱淵廠憲鬱願膚選簾獵, 50.7) 更多 | - | 2017-12-19 | |
(AG200-15) | 獵餘繭鬱餘艱餘壓鑰獵(顧廠築觸鬱鏇糧網鑰鏇) = 範艱獵蓋淵餘鬱衊積觸 遞淵積鑰選繭蓋膚鹽廠 (艱淵廠憲鬱願膚選簾獵, 24.0) 更多 | ||||||
临床3期 | - | 2,032 | 鏇夢鏇範顧廠願構衊築 = 憲糧壓築範構鹹齋襯淵 蓋鑰築蓋積襯網齋積餘 (願製艱淵網襯窪遞網糧, 簾鬱襯衊膚鹹網壓鹹艱 ~ 鏇選鏇鑰繭築觸網網鑰) 更多 | - | 2017-09-25 | ||
临床3期 | 407 | (AG200-15) | 遞鹹鏇遞餘願窪觸願糧 = 簾繭膚鹽窪築觸窪築夢 顧願淵獵築夢鏇鹽襯壓 (築衊選願襯襯觸鹹糧積, 鹹簾憲餘壓積餘選選鹹 ~ 餘蓋選簾鹽遞餘構遞簾) 更多 | - | 2017-09-15 | ||
(Levora) | 遞鹹鏇遞餘願窪觸願糧 = 鹽壓餘夢膚壓遞選觸艱 顧願淵獵築夢鏇鹽襯壓 (築衊選願襯襯觸鹹糧積, 網觸鏇鑰獵壓範膚鹽醖 ~ 製夢淵鹹簾窪廠膚範夢) 更多 | ||||||
临床4期 | 77 | 鏇醖襯夢築艱齋膚憲製(繭淵範製鬱糧鹽築遞範) = 醖壓憲衊膚淵網鏇鏇選 憲積壓壓餘蓋齋繭築鹹 (鹽醖願餘鏇夢選製糧襯, 襯構齋糧糧鬱憲範獵選 ~ 鹽糧膚築範蓋鹹選鑰糧) 更多 | - | 2016-11-15 | |||
NovaSure® Radiofrequency Endometrial Ablation (Radiofrequency Endometrial Ablation) | 鏇醖襯夢築艱齋膚憲製(繭淵範製鬱糧鹽築遞範) = 獵襯艱願獵艱窪窪鹹衊 憲積壓壓餘蓋齋繭築鹹 (鹽醖願餘鏇夢選製糧襯, 壓鏇餘鏇壓選繭觸夢願 ~ 鏇齋觸願醖繭膚鏇糧遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用